GFAP and Alzheimer disease: GFAP has emerged as a more accurate indicator of Aβ positivity compared with other glial markers, and it has been shown to predict longitudinal deposition in whole samples, regardless of the participants' cognitive status or the presence of AD or other neurodegenerative disorders73.